polycarbonate-ultracentrifuge-tube-re-use-proteomic-analyses

Polycarbonate Ultracentrifuge Tube Re-Use in Proteomic Analyses of Extracellular Vesicles

Single-use laboratory plastics exacerbate the pollution crisis and contribute to consumable costs. In extracellular vesicle (EV) isolation, polycarbonate ...

Brigham and Women’s Hospital, Harvard Medical School

In calcific aortic valve disease (CAVD), microcalcifications originating from nanoscale calcifying vesicles disrupt the aortic valve (AV) leaflets, which consist of three (biomechanically) distinct layers: the fibrosa, spongiosa, and ventricularis. CAVD has no pharmacotherapy and lacks in vitro models as a result of complex valvular biomechanical features surrounding resident mechanosensitive valvular interstitial cells (VICs). We measured layer-specific mechanical properties of the human AV and engineered a three-dimensional (3D)-bioprinted CAVD model that recapitulates leaflet layer biomechanics for the first time. Human AV leaflet layers were separated by microdissection, and nanoindentation determined layer-specific Young&rsquo;s moduli. Methacrylated gelatin (GelMA)/methacrylated hyaluronic acid (HAMA) hydrogels were tuned to duplicate layer-specific mechanical characteristics, followed by 3D-printing with encapsulated human VICs. Hydrogels were exposed to osteogenic media (OM) to induce microcalcification, and VIC pathogenesis was assessed by near infrared or immunofluorescence microscopy. Median Young&rsquo;s moduli of the AV layers were 37.1, 15.4, and 26.9 kPa (fibrosa/spongiosa/ventricularis, respectively). The fibrosa and spongiosa Young&rsquo;s moduli matched the 3D 5% GelMa/1% HAMA UV-crosslinked hydrogels. OM stimulation of VIC-laden bioprinted hydrogels induced microcalcification without apoptosis. We report the first layer-specific measurements of human AV moduli and a novel 3D-bioprinted CAVD model that potentiates microcalcification by mimicking the native AV mechanical environment. This work sheds light on valvular mechanobiology and could facilitate high-throughput drug-screening in CAVD.

Mark C. Blaser

Center for Interdisciplinary Cardiovascular Sciences,
Cardiovascular Division,
Department of Medicine,
Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Division, Department of Medicine

Brigham and Women’s Hospital, Harvard Medical School

Polycarbonate Ultracentrifuge Tube Re-Use in Proteomic Analyses of Extracellular Vesicles

Mark C. Blaser

Center for Interdisciplinary Cardiovascular Sciences,Cardiovascular Division,Department of Medicine,Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Division, Department of Medicine

Brigham and Women’s Hospital, Harvard Medical School

Polycarbonate Ultracentrifuge Tube Re-Use in Proteomic Analyses of Extracellular Vesicles

Center for Interdisciplinary Cardiovascular Sciences,
Cardiovascular Division,
Department of Medicine,
Center for Interdisciplinary Cardiovascular Sciences, Cardiovascular Division, Department of Medicine